英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
governi查看　governi　在百度字典中的解释百度英翻中〔查看〕
governi查看　governi　在Google字典中的解释Google英翻中〔查看〕
governi查看　governi　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • TEVIMBRA - accessdata. fda. gov
    1 INDICATIONS AND USAGE 1 1 Esophageal Cancer First-Line Treatment of Esophageal Squamous Cell Carcinoma TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1)
  • Oncology Drug Reference Sheet: Tislelizumab-Jsgr - ons. org
    Tislelizumab-jsgr (Tevimbra®) is a programmed cell death protein-1 (PD-1) blocking antibody approved in the United States in 2024 for the treatment of certain esophageal and gastric cancers It is administered via IV and works by enhancing the immune system’s ability to target cancer cells
  • Tislelizumab: Side Effects, Uses, Dosage, Interactions, Warnings
    Tislelizumab is a prescription medication indicated for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) in patients previously treated with systemic chemotherapy that did not include a PD-(L) 1 inhibitor
  • Success Rate of Immunotherapy for Esophageal Cancer: What . . .
    Learn about the success rate of immunotherapy for esophageal cancer, including survival outcomes, trial data, and PD-L1-based treatment responses
  • First-Line Tislelizumab Plus Chemotherapy Approved in ESCC . . .
    The FDA today approved tislelizumab (Tevimbra; BeiGene) plus chemotherapy for the first-line treatment of patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose
  • Tevimbra: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Tevimbra is used to treat adults with certain types of esophageal squamous cell carcinoma (ESCC), gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma that has spread (metastasized) or cannot be surgically removed
  • Cost-effectiveness analysis of tislelizumab vs. camrelizumab . . .
    Tislelizumab is a selective PD-1 inhibitor with efficacy proven in locally advanced or metastatic esophageal squamous cell carcinoma The study aims to evaluate the cost-effectiveness of tislelizumab versus camrelizumab as the second-line treatment in locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients in China
  • Tislelizumab Dosage Guide + Max Dose, Adjustments - Drugs. com
    Detailed Tislelizumab dosage information for adults Includes dosages for Esophageal Carcinoma and Gastric Cancer; plus renal, liver and dialysis adjustments
  • Tislelizumab combined with chemotherapy as neoadjuvant . . .
    Abstract Background Clinical benefit of neoadjuvant immunotherapy in resectable esophageal squamous cell carcinoma (ESCC) remains unclear This study evaluated the efficacy and safety of the programmed death 1 (PD-1) inhibitor tislelizumab combined with chemotherapy as neoadjuvant therapy in patients with resectable ESCC
  • 4-Year Results: Tislelizumab Plus Chemo for Esophageal Cancer
    Esophageal squamous cell carcinoma ranks among the deadliest of gastrointestinal cancers, with historically poor prognosis and limited long-term survival Traditional treatment paradigms often involve surgery alone or in combination with chemotherapy and radiation, but recurrence rates remain worryingly high





中文字典-英文字典  2005-2009